Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
RedactPHI
HIPAA-Compliant PHI Redaction
DetectICD10CM
ICD-10-CM Code Detection
Log in Register free account
1 code page views remaining. Guest accounts are limited to 1 page view. Register free account to get 5 more views.
Log in Register free account

Official Description

Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use

© Copyright 2025 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 90734 refers to a specific type of meningococcal conjugate vaccine designed to protect against meningococcal disease caused by the bacterium Neisseria meningitides. This vaccine is a quadrivalent formulation, meaning it targets four distinct serogroups: A, C, W, and Y. The vaccine utilizes either diphtheria toxoid (MenACWY-D) or a mutant form of diphtheria toxin known as CRM197 (MenACWY-CRM) as a carrier protein to enhance the immune response. Meningococcal disease can lead to severe health complications, including septicemia and meningitis, and is transmitted through respiratory secretions. The vaccine works by introducing capsular polysaccharide antigens from each of the four serogroups, which are conjugated to the carrier protein. This process stimulates the immune system to produce antibodies that recognize and combat these pathogens. Notably, MenACWY-CRM is approved for use in infants aged 2 to 8 months, particularly for those at increased risk of meningococcal disease, while MenACWY-D is indicated for children aged 9 to 12 months. It is important to note that this code specifically accounts for the supply of the vaccine itself; the administration of the vaccine via intramuscular injection is reported separately.

© Copyright 2025 Coding Ahead. All rights reserved.

1. Indications

The meningococcal conjugate vaccine, represented by CPT® Code 90734, is indicated for the prevention of meningococcal disease caused by serogroups A, C, W, and Y. This vaccine is particularly recommended for individuals at increased risk of contracting meningococcal disease, including:

  • Infants aged 2 through 8 months who are at heightened risk for meningococcal disease.
  • Children aged 9 to 12 months who may require vaccination against these specific serogroups.

2. Procedure

The administration of the meningococcal conjugate vaccine involves several key procedural steps, which are outlined as follows:

  • Step 1: Preparation of the Vaccine The vaccine must be prepared according to the manufacturer's guidelines. This includes checking the expiration date, ensuring the vaccine is stored at the correct temperature, and gently mixing the vaccine if necessary to ensure uniformity.
  • Step 2: Patient Assessment Prior to administration, a thorough assessment of the patient’s medical history should be conducted. This includes checking for any contraindications to vaccination, such as severe allergic reactions to any component of the vaccine.
  • Step 3: Site Selection The vaccine is administered via intramuscular injection, typically in the deltoid muscle of the upper arm for older children and adults, or in the anterolateral thigh for infants and young children.
  • Step 4: Administration of the Vaccine Using a sterile technique, the healthcare provider will inject the vaccine into the selected site. It is important to follow proper injection protocols to minimize discomfort and ensure effective delivery of the vaccine.
  • Step 5: Post-Administration Care After the vaccine is administered, the patient should be monitored for a short period for any immediate adverse reactions. Patients should be informed about potential side effects and the importance of follow-up vaccinations if required.

3. Post-Procedure

Following the administration of the meningococcal conjugate vaccine, patients may experience mild side effects such as soreness at the injection site, low-grade fever, or fatigue. These effects are generally short-lived and resolve without intervention. It is essential to provide patients with information regarding these potential reactions and to advise them to seek medical attention if they experience any severe or unusual symptoms. Additionally, healthcare providers should ensure that patients understand the importance of completing the vaccination series as recommended to achieve optimal protection against meningococcal disease.

Short Descr MENACWYD/MENACWYCRM VACC IM
Medium Descr MENACWYD/MENACWY-CRM CONJ VACC GRPS ACWY IM USE
Long Descr Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use
Status Code Excluded from Physician Fee Schedule by Regulation
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
APC Status Indicator Items and Services Not Billable to the MAC
Type of Service (TOS) 1 - Medical Care
Berenson-Eggers TOS (BETOS) T2D - Other tests - other
MUE 1
CCS Clinical Classification 228 - Prophylactic vaccinations and inoculations
GY Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
95 Synchronous telemedicine service rendered via a real-time interactive audio and video telecommunications system: synchronous telemedicine service is defined as a real-time interaction between a physician or other qualified health care professional and a patient who is located at a distant site from the physician or other qualified health care professional. the totality of the communication of information exchanged between the physician or other qualified health care professional and the patient during the course of the synchronous telemedicine service must be of an amount and nature that would be sufficient to meet the key components and/or requirements of the same service when rendered via a face-to-face interaction. modifier 95 may only be appended to the services listed in appendix p. appendix p is the list of cpt codes for services that are typically performed face-to-face, but may be rendered via a real-time (synchronous) interactive audio and video telecommunications system.
AH Clinical psychologist
AT Acute treatment (this modifier should be used when reporting service 98940, 98941, 98942)
CC Procedure code change (use 'cc' when the procedure code submitted was changed either for administrative reasons or because an incorrect code was filed)
CR Catastrophe/disaster related
FQ The service was furnished using audio-only communication technology
GA Waiver of liability statement issued as required by payer policy, individual case
GC This service has been performed in part by a resident under the direction of a teaching physician
GV Attending physician not employed or paid under arrangement by the patient's hospice provider
GW Service not related to the hospice patient's terminal condition
GX Notice of liability issued, voluntary under payer policy
GZ Item or service expected to be denied as not reasonable and necessary
JZ Zero drug amount discarded/not administered to any patient
SK Member of high risk population (use only with codes for immunization)
X1 Continuous/broad services: for reporting services by clinicians, who provide the principal care for a patient, with no planned endpoint of the relationship; services in this category represent comprehensive care, dealing with the entire scope of patient problems, either directly or in a care coordination role; reporting clinician service examples include, but are not limited to: primary care, and clinicians providing comprehensive care to patients in addition to specialty care
Date
Action
Notes
2020-01-01 Changed First appearance of change in code book.
2019-07-01 Changed Code description changed.
2019-01-01 Changed Code description changed.
2017-01-01 Changed Long, Medium and Short descriptions changed.
2016-01-01 Changed First appearance of change in codebook.
2015-07-01 Changed Description Changed
2015-01-01 Changed Description Changed
2011-01-01 Changed Short description changed.
2004-01-01 Added First appearance in code book in 2004.
Code
Description
Code
Description
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"